-+ 0.00%
-+ 0.00%
-+ 0.00%

Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate

Benzinga·11/20/2025 13:30:31
Listen to the news
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent. This is a 65 percent increase over losses of $(0.80) per share from the same period last year.